Assessing exercise capacity in heart failure patients with microvascular dysfunction and body composition analysis
Official title: Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients With Suspected Heart Failure With Preserved Ejection Fraction
Run by Korea University Anam Hospital · NCT04822649 · Data updated 2026-11-12
This study is testing how heart function, body makeup, and exercise ability are connected in people with heart failure who have chest pain but no blocked arteries.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Korea University Anam Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | April 15, 2021 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | September 2, 2025 |
| Trial ID | NCT04822649 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 20 to 80 with chest pain or ischemic symptoms and preserved ejection fraction without significant coronary artery stenosis.
✕Probably not a fit
Patients with significant valvular heart disease, chronic respiratory conditions, or those unable to perform exercise evaluations may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the relationship between coronary microvascular function, body composition, and exercise capacity in patients suffering from heart failure with preserved ejection fraction (HFpEF). Participants will be selected based on specific criteria, including the presence of chest pain or ischemic symptoms and non-obstructive coronary artery disease. They will undergo body composition analysis and adenosine stress echocardiography to assess coronary blood flow, alongside a cardiopulmonary exercise test to measure maximal oxygen consumption. The study aims to correlate coronary flow reserve with exercise capacity and body composition metrics.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of exercise limitations in patients with HFpEF.
How similar studies have gone: While studies on coronary microvascular dysfunction and exercise capacity exist, this specific correlation with body composition in HFpEF patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 20 to 80 * Typical/atypical chest pain or ischemic symptoms including dyspnea * No significant coronary artery stenosis (\>50% stenosis) in coronary angiography or computed tomography * Left ventricular ejection fraction ≥50% Exclusion Criteria: * More than moderate valvular heart disease * Congenital heart disease * Chronic renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis * Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension * Receiving anticancer drugs * Vasculitis associated with autoimmune diseases * Patients with difficulty in performing exercise load evaluation (treadmill, bicycle ergometer) * Atrial fibrillation * Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients
Where it's running
-
Korea University Anam Hospital
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: So Ree Kim, MD
- Email: soree8826kim@gmail.com
- Phone: 821094534810
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease
This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
Resmetirom for MASH with HFpEF in adults
This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.
-
Elecoglipron vs placebo for adults with HFpEF or HFmrEF
This Phase 3 study tests whether elecoglipron helps people with HFpEF or HFmrEF who are on dapagliflozin and standard care.
-
Iron infusion and MRI to study inflammation in HFpEF
A small early-phase study tests whether an iron infusion affects heart inflammation in people with HFpEF, using MRI measures before and after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.